These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

976 related articles for article (PubMed ID: 8313400)

  • 21. Monoamine oxidase, monoamine oxidase inhibitors, and panic disorder.
    Norman TR; Burrows GD
    J Neural Transm Suppl; 1989; 28():53-63. PubMed ID: 2677243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression.
    Ketter TA; Post RM; Parekh PI; Worthington K
    J Clin Psychiatry; 1995 Oct; 56(10):471-5. PubMed ID: 7559374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A controlled double-blind trial of moclobemide and imipramine in the treatment of depression.
    Kok LP; Tsoi WF
    Singapore Med J; 1995 Feb; 36(1):38-40. PubMed ID: 7570133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of depressions resistant to tricyclic antidepressants, related drugs or MAO-inhibitors by lithium addition: review of the literature.
    Schöpf J
    Pharmacopsychiatry; 1989 Sep; 22(5):174-82. PubMed ID: 2682691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression.
    Thomas SJ; Shin M; McInnis MG; Bostwick JR
    Pharmacotherapy; 2015 Apr; 35(4):433-49. PubMed ID: 25884531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic and side-effect profile of a selective and reversible MAO-A inhibitor, brofaromine. Results of dose-finding trials in depressed patients.
    Schiwy W; Heath WR; Delini-Stula A
    J Neural Transm Suppl; 1989; 28():33-44. PubMed ID: 2677240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of depression in the elderly.
    Williams GO
    Prim Care; 1989 Jun; 16(2):451-74. PubMed ID: 2664841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
    Youdim MB; Weinstock M
    Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tyramine and new monoamine oxidase inhibitor drugs.
    Simpson GM; de Leon J
    Br J Psychiatry Suppl; 1989 Oct; (6):32-7. PubMed ID: 2695125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monoamine oxidase inhibitors in resistant major depression. A double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants.
    Nolen WA; Haffmans PM; Bouvy PF; Duivenvoorden HJ
    J Affect Disord; 1993 Jul; 28(3):189-97. PubMed ID: 8408980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trimipramine and maprotiline plasma levels during combined treatment with moclobemide in therapy-resistant depression.
    König F; Wolfersdorf M; Löble M; Wössner S; Hauger B
    Pharmacopsychiatry; 1997 Jul; 30(4):125-7. PubMed ID: 9271778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current place of monoamine oxidase inhibitors in the treatment of depression.
    Shulman KI; Herrmann N; Walker SE
    CNS Drugs; 2013 Oct; 27(10):789-97. PubMed ID: 23934742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dietary restrictions and drug interactions with monoamine oxidase inhibitors: the state of the art.
    Rapaport MH
    J Clin Psychiatry; 2007; 68 Suppl 8():42-6. PubMed ID: 17640157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Rational use of antidepressants in general medicine].
    Verbanck P; Cnockaert P
    Rev Med Brux; 1996 Sep; 17(4):224-9. PubMed ID: 8927850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine.
    Lavian G; Finberg JP; Youdim MB
    Clin Neuropharmacol; 1993; 16 Suppl 2():S1-7. PubMed ID: 8313392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pharmacology of reversible monoamine oxidase inhibitors.
    Amrein R; Allen SR; Guentert TW; Hartmann D; Lorscheid T; Schoerlin MP; Vranesic D
    Br J Psychiatry Suppl; 1989 Oct; (6):66-71. PubMed ID: 2695128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential response patterns to MAO inhibitors and tricyclics.
    Nies A
    J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):70-7. PubMed ID: 6376487
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide.
    Nair NP; Ahmed SK; Kin NM
    J Psychiatry Neurosci; 1993 Nov; 18(5):214-25. PubMed ID: 7905288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brofaromine--a selective, reversible, and short-acting MAO-A inhibitor: review of the pharmacological and clinical findings.
    Möller HJ; Wendt G; Waldmeier P
    Pharmacopsychiatry; 1991 Mar; 24(2):50-4. PubMed ID: 1852792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Moclobemide].
    Gleiter C; Volz HP
    Dtsch Med Wochenschr; 1995 Aug; 120(34-35):1175-6. PubMed ID: 7656852
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.